At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Jul 15, 2026 at 16:20 ET
Telix Pharmaceuticals announced first patient dosing in the Phase 2 OPTIMAL-e trial evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer. This is an early-stage clinical milestone with no financial data or regulatory decision, representing a routine pipeline update for a commercial-stage radiopharmaceutical company.
- First patients dosed in Phase 2 OPTIMAL-e trial of TLX597-Tx for mHSPC at St Vincent's Hospital Sydney
- OPTIMAL-e is a single-arm, open-label pilot study evaluating adaptive-dosed TLX597-Tx with ADT and ARPI
- TLX597-Tx has not received marketing authorization in any jurisdiction
- TLX597-Tx is a next-generation PSMA-targeting small molecule radioligand therapy candidate
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access